ASCO GU 2013 Tivozanib TIVO-1 Hypoxia Signature ccRCC – Abstract 361, Robinson

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)